Citizens Business Bank Has $1.90 Million Position in Edwards Lifesciences Co. (NYSE:EW)

Citizens Business Bank lessened its holdings in Edwards Lifesciences Co. (NYSE:EW) by 22.6% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 25,696 shares of the medical research company’s stock after selling 7,493 shares during the period. Citizens Business Bank’s holdings in Edwards Lifesciences were worth $1,902,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Deutsche Bank AG lifted its position in shares of Edwards Lifesciences by 10.4% during the 4th quarter. Deutsche Bank AG now owns 6,903,202 shares of the medical research company’s stock worth $511,044,000 after buying an additional 652,923 shares during the period. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main boosted its stake in shares of Edwards Lifesciences by 70.0% in the 4th quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 75,911 shares of the medical research company’s stock valued at $5,620,000 after purchasing an additional 31,264 shares in the last quarter. EP Wealth Advisors LLC grew its holdings in shares of Edwards Lifesciences by 50.8% in the 4th quarter. EP Wealth Advisors LLC now owns 30,543 shares of the medical research company’s stock worth $2,261,000 after purchasing an additional 10,283 shares during the last quarter. Colonial Trust Co SC increased its position in shares of Edwards Lifesciences by 4.4% during the 4th quarter. Colonial Trust Co SC now owns 32,679 shares of the medical research company’s stock worth $2,419,000 after purchasing an additional 1,364 shares in the last quarter. Finally, Centiva Capital LP lifted its holdings in Edwards Lifesciences by 103.8% during the 4th quarter. Centiva Capital LP now owns 9,110 shares of the medical research company’s stock valued at $674,000 after purchasing an additional 4,641 shares during the last quarter. Institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Stock Performance

NYSE EW opened at $75.01 on Thursday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. Edwards Lifesciences Co. has a fifty-two week low of $58.93 and a fifty-two week high of $95.25. The stock has a market cap of $44.10 billion, a PE ratio of 10.76, a PEG ratio of 4.82 and a beta of 1.12. The firm’s fifty day moving average price is $71.37 and its two-hundred day moving average price is $71.44.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $0.64 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.60 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. The firm had revenue of $1.41 billion during the quarter, compared to analyst estimates of $1.40 billion. During the same quarter last year, the business earned $0.66 EPS. The company’s revenue was up 6.2% compared to the same quarter last year. On average, equities analysts expect that Edwards Lifesciences Co. will post 2.45 EPS for the current fiscal year.

Insider Transactions at Edwards Lifesciences

In other Edwards Lifesciences news, CEO Bernard J. Zovighian sold 6,164 shares of the company’s stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $69.51, for a total value of $428,459.64. Following the transaction, the chief executive officer now directly owns 59,083 shares in the company, valued at $4,106,859.33. This represents a 9.45 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Daniel J. Lippis sold 400 shares of the stock in a transaction on Monday, March 10th. The stock was sold at an average price of $69.48, for a total transaction of $27,792.00. Following the completion of the transaction, the vice president now directly owns 22,588 shares in the company, valued at $1,569,414.24. The trade was a 1.74 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 77,833 shares of company stock worth $5,611,023 in the last quarter. Insiders own 1.29% of the company’s stock.

Analysts Set New Price Targets

Several analysts have recently weighed in on EW shares. Stifel Nicolaus raised shares of Edwards Lifesciences from a “hold” rating to a “buy” rating and raised their price objective for the stock from $75.00 to $90.00 in a report on Thursday, January 30th. Wolfe Research downgraded Edwards Lifesciences from a “hold” rating to a “strong sell” rating in a research report on Wednesday, February 12th. Morgan Stanley increased their target price on Edwards Lifesciences from $70.00 to $75.00 and gave the stock an “equal weight” rating in a report on Wednesday, February 12th. Robert W. Baird lifted their price target on Edwards Lifesciences from $72.00 to $75.00 and gave the company a “neutral” rating in a report on Thursday, April 24th. Finally, Piper Sandler upgraded shares of Edwards Lifesciences from a “neutral” rating to an “overweight” rating and upped their price target for the stock from $73.00 to $80.00 in a research report on Thursday, April 24th. One investment analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and eleven have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $79.45.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.